Inclisiran与bempedoic acid在高危患者中降低LDL-C的头对头比较:VICTORION-Challenge试验
VICTORION-Challenge是一项4期开放标签研究,纳入402例接受他汀(±依折麦布)且LDL-C≥70 mg/dL的ASCVD患者,随机接受inclisiran或bempedoic acid治疗。第150天时,inclisiran组LDL-C降幅显著优于bempedoic acid组(-56.3% vs -15.4%),且达标率更高(78.2% vs 20.3%),安全性良好。
要点
- inclisiran降低LDL-C幅度显著优于bempedoic acid,组间差异达-41.0%。
- inclisiran的LDL-C达标率显著高于bempedoic acid(78.2% vs 20.3%)。
- inclisiran安全性良好,治疗中出现的不良事件发生率与bempedoic acid相当。
核心结论
- 在高危ASCVD患者中,inclisiran降低LDL-C的疗效显著优于bempedoic acid,且安全性良好,支持其用于未达到指南推荐目标的患者。
研究设计与样本
- 4期、开放标签、随机对照研究,纳入402例接受他汀(±依折麦布)且LDL-C≥70 mg/dL的ASCVD患者,随机分配至inclisiran组或bempedoic acid组。
主要发现
- 第150天时,inclisiran组LDL-C降幅为-56.3%,bempedoic acid组为-15.4%,组间差异为-41.0%(95%CI -45.7至-36.2;p<0.0001)。
- inclisiran组LDL-C绝对降幅为-53.4 mg/dL,bempedoic acid组为-17.5 mg/dL,且不受是否使用依折麦布影响。
- inclisiran组LDL-C达标率为78.2%,bempedoic acid组为20.3%(校正比值比16.36,95%CI 9.72至27.54;描述性p<0.0001)。
- inclisiran组与bempedoic acid组治疗中出现的不良事件发生率分别为63.1%和59.8%,严重不良事件发生率分别为5.9%和7.5%。
临床怎么用
- 对于接受他汀(±依折麦布)但LDL-C仍未达标的高危ASCVD患者,inclisiran可作为优于bempedoic acid的降脂选择。
局限性
- 本研究为开放标签设计,可能引入偏倚;样本量有限(402例),需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Low-density lipoprotein cholesterol (LDL-C) targets remain unmet in many high-risk atherosclerotic cardiovascular disease (ASCVD) patients on statins (± ezetimibe). VICTORION-Challenge compared inclisiran with bempedoic acid (BPA) for LDL-C lowering and target attainment in these patients, directly. METHODS: In this phase 4, open-label study, ASCVD patients with LDL-C ≥70 mg/dL on statins (± ezetimibe) were randomized to inclisiran or BPA. The primary endpoint was percentage change in LDL-C at Day 150; key secondary endpoints at Day 150 included percentage LDL-C change stratified by ezetimibe use. Secondary endpoints included LDL-C goal attainment and absolute change; treatment-emergent adverse events (TEAEs) were evaluated. RESULTS: Among 402 randomized patients (mean±standard deviation age, 63.1±10.7 years; 64.2% men; baseline LDL-C 94.4±28.3 mg/dL), LDL-C reduction at Day 150 was superior with inclisiran vs BPA (least squares mean -56.3% vs -15.4%; between-group difference -41.0%, 95% confidence interval [CI] -45.7 to -36.2; p<0.0001). Inclisiran achieved greater absolute LDL-C reduction at Day 150 (-53.4 vs -17.5 mg/dL) regardless of ezetimibe use, with higher LDL-C goal attainment (78.2% vs 20.3%; adjusted odds ratio 16.36, 95% CI 9.72 to 27.54; descriptive p<0.0001). Inclisiran showed a favourable safety profile vs BPA, with comparable rates of TEAEs (63.1% vs 59.8%) and serious TEAEs (5.9% vs 7.5%). Most common TEAEs (inclisiran vs BPA) included nasopharyngitis (10.3% vs 7.5%), hypertension (4.9% vs 4.5%), and myalgia (3.4% vs 5.5%). One non-treatment-related death (inclisiran) was reported. CONCLUSIONS: Inclisiran provided superior LDL-C reduction versus BPA with favourable safety, supporting its use in high-risk patients not achieving guideline-recommended goals.
引用
- Hilgendorf I, Westermann D, Nowak B, et al. Inclisiran vs bempedoic acid for low-density lipoprotein cholesterol lowering in high-risk patients: the VICTORION-Challenge trial. Eur Heart J. 2026. PMID: 42670194. doi:10.1093/eurheartj/ehag738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。